Sanofi-Aventis invests in new diabetes agent

Friday 25 June 2010

Sanofi-Aventis SA has entered into a licensing agreement with Metabolex Inc of the US to develop a novel treatment for Type 2 diabetes that targets the G protein-coupled receptor 119. The deal could be valued at $375 million if a product is commercialised.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France